Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: National Multiple Sclerosis Society; Teva Neuroscience, Inc.
• Treatments: (T,G)-A-L; Anti-Inflammatory Agents; Glatiramer Acetate

Criteria

Inclusion Criteria:

• Relapsing-remitting (RR) MS patients (McDonald criteria)

• Ages 18-55

• Males and females

• EDSS score ≤5

• No prior treatment with Copaxone

• Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month

Exclusion Criteria:

• Treatment with Tysabri, Novantrone or cyclophosphamide

• Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate)

• Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis

• Pregnancy